Publications
Recent publications (selected, updated 04/2022):
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM
.J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10.PMID: 35143285
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC, Jansen P, Möller I, Sucker A, Hassel JC, Forschner A, Eckardt J, Meier F, Reinhardt L, Kähler KC, Ziemer M, Schlaak M, Rahimi F, Schatton K, Meiss F, Gutzmer R, Pföhler C, Terheyden P, Schilling B, Sachse M, Heppt MV, Sindrilaru A, Leiter U, Zaremba A, Thielmann CM, Ugurel S, Zimmer L, Hadaschik E, Bechrakis NE, Schadendorf D, Westekemper H, Livingstone E, Griewank KG; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma).
Eur J Cancer. 2022 May;166:60-72. doi: 10.1016/j.ejca.2022.01.008. Epub 2022 Mar 10.PMID: 35279471
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I, Ugurel S, Kubat L, Zimmer L, Terheyden P, Mohr A, Björn Andtback H, Villabona L, Leiter U, Eigentler T, Loquai C, Hassel JC, Gambichler T, Haferkamp S, Mohr P, Pfoehler C, Heinzerling L, Gutzmer R, Utikal JS, Horny K, Schildhaus HU, Habermann D, Hoffmann D, Schadendorf D, Becker JC.
J Immunother Cancer. 2022 Jan;10(1):e003198. doi: 10.1136/jitc-2021-003198.PMID: 35074902
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Griewank KG.
Eur J Cancer. 2022 Jan;161:99-107. doi: 10.1016/j.ejca.2021.11.009. Epub 2021 Dec 20.PMID: 34936949
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, Jansen P, Richter L, Kretz J, Möller I, Sucker A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Paschen A, Livingstone E, Zimmer L, Schadendorf D, Hadaschik E, Ugurel S, Griewank KG.
Eur J Cancer. 2021 Dec;159:113-124. doi: 10.1016/j.ejca.2021.09.035. Epub 2021 Nov 4.PMID: 34742158
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Zimmer L, Livingstone E, Becker JC, Lodde G, Sucker A, Griewank K, Horn S, Hadaschik E, Roesch A, Schadendorf D, Engel DR, Ugurel S.
Front Oncol. 2021 Sep 21;11:741993. doi: 10.3389/fonc.2021.741993. eCollection 2021.PMID: 34621681
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma.
Ferdinandus J, Fendler WP, Lueckerath K, Berliner C, Kurzidem S, Hadaschik E, Klode J, Zimmer L, Livingstone E, Schadendorf D, Herrmann K, Becker JC, Ugurel S.
J Nucl Med. 2022 Mar;63(3):396-398. doi: 10.2967/jnumed.121.262344. Epub 2021 Sep 2.PMID: 34475234
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Westphal D, Garzarolli M, Sergon M, Horak P, Hutter B, Becker JC, Wiegel M, Maczey E, Blum S, Grosche-Schlee S, Rütten A, Ugurel S, Stenzinger A, Glimm H, Aust D, Baretton G, Beissert S, Fröhling S, Redler S, Surowy H, Meier F.
Br J Dermatol. 2021 Dec;185(6):1186-1199. doi: 10.1111/bjd.20604. Epub 2021 Aug 18.PMID: 34185311
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.
Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T.
Eur Heart J. 2022 Jan 31;43(4):316-329. doi: 10.1093/eurheartj/ehab430.PMID: 34389849
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.
Koch EAT, Petzold A, Wessely A, Dippel E, Gesierich A, Gutzmer R, Hassel JC, Haferkamp S, Hohberger B, Kähler KC, Knorr H, Kreuzberg N, Leiter U, Loquai C, Meier F, Meissner M, Mohr P, Pföhler C, Rahimi F, Schadendorf D, Schell B, Schlaak M, Terheyden P, Thoms KM, Schuler-Thurner B, Ugurel S, Ulrich J, Utikal J, Weichenthal M, Ziller F, Berking C, Heppt MV, On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma.
Cancers (Basel). 2021 Jul 4;13(13):3359. doi: 10.3390/cancers13133359.PMID: 34283061
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.
Kähler KC, Gutzmer R, Meier F, Zimmer L, Heppt M, Gesierich A, Thoms KM, Utikal J, Hassel JC, Loquai C, Pföhler C, Heinzerling L, Kaatz M, Göppner D, Pflugfelder A, Bohne AS, Satzger I, Reinhardt L, Placke JM, Schadendorf D, Ugurel S.
Front Oncol. 2021 May 24;11:672172. doi: 10.3389/fonc.2021.672172. eCollection 2021.PMID: 34109122
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Stege H, Haist M, Schultheis M, Fleischer MI, Mohr P, Meier F, Schadendorf D, Ugurel S, Livingstone E, Zimmer L, Herbst R, Pföhler C, Kähler K, Weichenthal M, Terheyden P, Nashan D, Debus D, Kaatz M, Ziller F, Haferkamp S, Forschner A, Leiter U, Kreuter A, Ulrich J, Kleemann J, Bradfisch F, Grabbe S, Loquai C.
Cancers (Basel). 2021 May 12;13(10):2312. doi: 10.3390/cancers13102312.PMID: 34065877
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases.
Franklin C, Wetter A, Baba HA, Theysohn J, Haubold J, Cosgarea I, Hadaschik E, Livingstone E, Zimmer L, Stoffels I, Klode J, Lodde G, Placke JM, Schadendorf D, Ugurel S.
Eur J Cancer. 2021 Jun;150:119-129. doi: 10.1016/j.ejca.2021.03.026. Epub 2021 Apr 23.PMID: 33895683
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, Becker JC, Meissner M, Kleeman J, Pföhler C, Hassel J, Grabbe S, Loquai C.
Cancer Immunol Immunother. 2021 Nov;70(11):3313-3322. doi: 10.1007/s00262-021-02925-4. Epub 2021 Apr 18.PMID: 33870464
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R; German Dermatooncology Group (DeCOG).
Eur J Cancer. 2021 May;149:1-10. doi: 10.1016/j.ejca.2021.02.017. Epub 2021 Mar 31.PMID: 33812141
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
Glutsch V, Kneitz H, Gesierich A, Goebeler M, Haferkamp S, Becker JC, Ugurel S, Schilling B.
Cancer Immunol Immunother. 2021 Jul;70(7):2087-2093. doi: 10.1007/s00262-020-02832-0. Epub 2021 Jan 13.PMID: 33439294
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53.
Fan K, Spassova I, Gravemeyer J, Ritter C, Horny K, Lange A, Gambichler T, Ødum N, Schrama D, Schadendorf D, Ugurel S, Becker JC.
Oncogene. 2021 Feb;40(5):980-996. doi: 10.1038/s41388-020-01576-6. Epub 2020 Dec 11.PMID: 33311552
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes.
Peiffer L, Farahpour F, Sriram A, Spassova I, Hoffmann D, Kubat L, Stoitzner P, Gambichler T, Sucker A, Ugurel S, Schadendorf D, Becker JC.
Cancer Immunol Immunother. 2021 Jun;70(6):1635-1647. doi: 10.1007/s00262-020-02804-4. Epub 2020 Dec 4.PMID: 33275172
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, Hassel JC, Glutsch V, Sirokay J, Schlecht N, Rübben A, Gambichler T, Schatton K, Pfoehler C, Franklin C, Terheyden P, Haferkamp S, Mohr P, Bischof L, Livingstone E, Zimmer L, Weichenthal M, Schadendorf D, Meiwes A, Keim U, Garbe C, Becker JC, Ugurel S.
J Immunother Cancer. 2020 Oct;8(2):e000897. doi: 10.1136/jitc-2020-000897.PMID: 33093156
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, Seifert U, Dittmer U, Schuler M, Lang KS, Kufer TA, Hartmann G, Becker JC, Horn S, Ferrone S, Liu D, Van Allen EM, Schadendorf D, Griewank K, Trilling M, Paschen A.
J Clin Invest. 2020 Aug 3;130(8):4266-4281. doi: 10.1172/JCI131572.PMID: 32427578
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, Pföhler C, Gesierich A, Herbst R, Kaehler KC, Weide B, Berking C, Loquai C, Utikal J, Terheyden P, Kaatz M, Schlaak M, Kreuter A, Ulrich J, Mohr P, Dippel E, Livingstone E, Becker JC, Weichenthal M, Chorti E, Gronewold J, Schadendorf D, Ugurel S.
J Immunother Cancer. 2020 May;8(1):e000395. doi: 10.1136/jitc-2019-000395.PMID: 32371460
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma.
Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT.
J Invest Dermatol. 2020 Nov;140(11):2146-2156.e4. doi: 10.1016/j.jid.2020.02.031. Epub 2020 Apr 15.PMID: 32304704
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.
Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C.
Eur J Cancer. 2020 May;130:126-138. doi: 10.1016/j.ejca.2020.02.021. Epub 2020 Mar 13.PMID: 32179447
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG.
Br J Dermatol. 2020 Nov;183(5):928-939. doi: 10.1111/bjd.18947. Epub 2020 Apr 13.PMID: 32064597
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, Kubat L, Habermann D, Farahpour F, Saeedghalati M, Peiffer L, Kumar R, Schrama D, Hoffmann D, Schadendorf D, Becker JC.
Clin Cancer Res. 2020 May 1;26(9):2257-2267. doi: 10.1158/1078-0432.CCR-19-2244. Epub 2020 Jan 13.PMID: 31932494
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, Pföhler C, Herbst R, Schilling B, Blank C, Becker JC, Paschen A, Zimmer L, Livingstone E, Horn PA, Rebmann V.
Ann Oncol. 2020 Jan;31(1):144-152. doi: 10.1016/j.annonc.2019.09.005.PMID: 31912789
